Research Article
A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network
Table 7
Degree centrality of promising drug candidates on the validation network.
| Rank | Drug name | Degree centrality |
| 1 | Tamoxifen | 0.661 | 2 | Doxorubicin | 0.554 | 3 | Paclitaxel | 0.536 | 4 | Fulvestrant | 0.268 | 5 | Methotrexate | 0.268 | 6 | Camptothecin | 0.232 | 7 | Letrozole | 0.214 | 8 | Vinblastine | 0.196 | 9 | Exemestane | 0.179 | 10 | Megestrol | 0.125 | 11 | Aminoglutethimide | 0.107 | 12 | MS-275 | 0.089 | 13 | Alsterpaullone | 0.071 | 14 | GW-8510 | 0.036 | 15 | Phenoxybenzamine | 0.036 | 16 | Celastrol | 0.036 | 17 | Tyrphostin_AG-825 | 0.018 |
|
|
Known breast cancer drug. Potential drug candidate for repositioning.
|